Atezolizumab, a mAb that targets PD-L1 and activates T cells and kills tumor cells by blocking their binding to PD-1 (Crist and Balar, 2017), was approved by the FDA in 2016 for the treatment of NSCLC (Table 1). Here, PDCD1 is linked to neoplasm.